NDAORALTABLET
Approved
Apr 2025
Lifecycle
Launch
Competitive Pressure
0/100
Clinical Trials
15
Mechanism of Action
(Ki = 0.034 nM) with >1800-fold selectivity for the ET A receptor compared to the endothelin type B receptor (Ki = 63.3 nM). Endothelin (ET)-1 is thought to contribute to the pathogenesis of IgAN via the ET A R.
Clinical Trials (5)
Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy
Started Jul 2023
54 enrolled
IgA NephropathyImmunoglobulin A Nephropathy
Atrasentan in Patients With Proteinuric Glomerular Diseases
Started Mar 2021
103 enrolled
IgA NephropathyFocal Segmental GlomerulosclerosisAlport Syndrome+3 more
Atrasentan Spermatogenesis and Testicular Function
Started Apr 2015
20 enrolled
NephropathyDiabetes
Study Of Diabetic Nephropathy With Atrasentan
Started May 2013
5,107 enrolled
Diabetic Nephropathy
Reducing Residual Albuminuria in Subjects With Diabetes and Nephropathy With Atrasentan
Started Aug 2011
58 enrolled
Chronic Kidney DiseaseDiabetic Nephropathy
Loss of Exclusivity
LOE Date
Feb 23, 2041
182 months away
Patent Expiry
Feb 23, 2041
Exclusivity Expiry
Apr 2, 2030